Literature DB >> 12076999

Nicotinic receptor abnormalities in the cerebellar cortex in autism.

M Lee1, C Martin-Ruiz, A Graham, J Court, E Jaros, R Perry, P Iversen, M Bauman, E Perry.   

Abstract

Autism is a common developmental disorder associated with structural and inferred neurochemical abnormalities of the brain. Cerebellar abnormalities frequently have been identified, based on neuroimaging or neuropathology. Recently, the cholinergic neurotransmitter system has been implicated on the basis of nicotinic receptor loss in the cerebral cortex. Cerebellar cholinergic activities were therefore investigated in autopsy tissue from a series of autistic individuals. The presynaptic cholinergic enzyme, choline acetyltransferase, together with nicotinic and muscarinic receptor subtypes were compared in the cerebellum from age-matched mentally retarded autistic (eight), normal control (10) and non-autistic mentally retarded individuals (11). The nicotinic receptor binding the agonist epibatidine (the high affinity receptor subtype, consisting primarily of alpha3 and alpha4, together with beta2 receptor subunits) was significantly reduced by 40-50% in the granule cell, Purkinje and molecular layers in the autistic compared with the normal group (P < 0.05). There was an opposite increase (3-fold) in the nicotinic receptor binding alpha-bungarotoxin (to the alpha7 subunit) which reached significance in the granule cell layer (P < 0.05). These receptor changes were paralleled by a significant reduction (P < 0.05) and non-significant increase, respectively, of alpha4 and alpha7 receptor subunit immunoreactivity measured using western blotting. Immunohistochemically loss of alpha(4 )reactivity was apparent from Purkinje and the other cell layers, with increased alpha7 reactivity in the granule cell layer. There were no significant changes in choline acetyltransferase activity, or in muscarinic M1 and M2 receptor subtypes in autism. In the non-autistic mentally retarded group, the only significant abnormality was a reduction in epibatidine binding in the granule cell and Purkinje layers. In two autistic cases examined histologically, Purkinje cell loss was observed in multiple lobules throughout the vermis and hemispheres. This was more severe in one case with epilepsy, which also showed vermis folial malformation. The case with less severe Purkinje cell loss also showed cerebellar white matter thinning and demyelination. These findings indicate a loss of the cerebellar nicotinic alpha4 receptor subunit in autism which may relate to the loss of Purkinje cells, and a compensatory increase in the alpha7 subunit. It remains to be determined how these receptor abnormalities are involved in neurodevelopment in autism and what is the relationship to mental function. Since nicotinic receptor agonists enhance attentional function and also induce an elevation in the high affinity receptor, nicotinic therapy in autism may be worth considering.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076999     DOI: 10.1093/brain/awf160

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  53 in total

Review 1.  Selective vulnerability of cerebellar granule neuroblasts and their progeny to drugs with abuse liability.

Authors:  Kurt F Hauser; Valeriya K Khurdayan; Robin J Goody; Avindra Nath; Alois Saria; James R Pauly
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

Review 2.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

3.  Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Authors:  L Eugene Arnold; Michael G Aman; Jill Hollway; Elizabeth Hurt; Bethany Bates; Xiaobai Li; Cristan Farmer; Rene Anand; Susan Thompson; Yaser Ramadan; Craig Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

4.  Rapid eye movement sleep percentage in children with autism compared with children with developmental delay and typical development.

Authors:  Ashura Williams Buckley; Alcibiades J Rodriguez; Kaitlin Jennison; Jack Buckley; Audrey Thurm; Susumu Sato; Susan Swedo
Journal:  Arch Pediatr Adolesc Med       Date:  2010-11

Review 5.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

6.  Presynaptic targeting of alpha4beta 2 nicotinic acetylcholine receptors is regulated by neurexin-1beta.

Authors:  Shi-Bin Cheng; Stephanie A Amici; Xiao-Qin Ren; Susan B McKay; Magdalen W Treuil; Jon M Lindstrom; Jayaraman Rao; Rene Anand
Journal:  J Biol Chem       Date:  2009-06-30       Impact factor: 5.157

7.  Neonatal nicotine exposure increases excitatory synaptic transmission and attenuates nicotine-stimulated GABA release in the adult rat hippocampus.

Authors:  Joanne C Damborsky; William H Griffith; Ursula H Winzer-Serhan
Journal:  Neuropharmacology       Date:  2014-06-17       Impact factor: 5.250

Review 8.  The Contribution of the Cerebellum in the Hierarchial Development of the Self.

Authors:  Mehmet Emin Ceylan; Aslıhan Dönmez; Barış Önen Ülsalver
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

Review 9.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

10.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.